Inhaled corticosteroid asthma

LABA+ICS群と比較し、LAMA+LABA群の統合された主要評価項目の結果は以下の通りである:増悪、OR (95%CI ~、P = 、I 2 = 17%、低い質のエビデンス);重篤な副作用、(95%CI ~、P = 、I 2 = 0%、中等度の質のエビデンス);St. George's Respiratory Questionnaire (SGRQ)ベースラインからの変化、MD -(95%CI ~、P = 、I 2 = 71%、低い質のエビデンス);トラフ一秒量ベースラインからの変化、MD (95%CI ~、P <、I 2 = 50%、中程度の質のエビデンス)。同様に二次評価項目の結果は以下の通りである:肺炎、OR (95%CI ~、P = 、I 2 = 0%、低い質のエビデンス);全死亡、OR (95%CI ~、P = 、I 2 = 0%、低い質のエビデンス)、臨床的有意な最小変化量(4点)以上のSGRQベースラインからの改善、OR (95%CI ~、P = 、I 2 = 0%、中等度の質のエビデンス)。

Use of QVAR with a spacer device in children less than 5 years of age is not recommended. In vitro dose characterization studies were performed with QVAR 40 mcg/actuation with the OptiChamber and AeroChamber Plus ® spacer utilizing inspiratory flows representative of children under 5 years old. These studies indicated that the amount of medication delivered through the spacing device decreased rapidly with increasing wait times of 5 to 10 seconds as shown in Table 2. If QVAR is used with a spacer device, it is important to inhale immediately.

Inhaled corticosteroid asthma

inhaled corticosteroid asthma

Media:

inhaled corticosteroid asthmainhaled corticosteroid asthmainhaled corticosteroid asthmainhaled corticosteroid asthmainhaled corticosteroid asthma

http://buy-steroids.org